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Mycoplasma pneumoniae is a cell wall-less bacterial pathogen of the human respiratory
tract that accounts for > 20% of all community-acquired pneumonia (CAP). At present the
most effective means for detection and strain-typing is quantitative polymerase chain reac-
tion (qPCR), which can exhibit excellent sensitivity and specificity but requires separate
tests for detection and genotyping, lacks standardization between available tests and
between labs, and has limited practicality for widespread, point-of-care use. We have devel-
oped and previously described a silver nanorod array-surface enhanced Raman Spectros-
copy (NA-SERS) biosensing platform capable of detectingM. pneumoniae with statistically
significant specificity and sensitivity in simulated and true clinical throat swab samples, and
the ability to distinguish between reference strains of the two main genotypes ofM. pneu-
moniae. Furthermore, we have established a qualitative lower endpoint of detection for NA-
SERS of < 1 genome equivalent (cell/μl) and a quantitative multivariate detection limit of 5.3
± 1 cells/μl. Here we demonstrate using partial least squares- discriminatory analysis (PLS-
DA) of sample spectra that NA-SERS correctly identifiedM. pneumoniae clinical isolates
from globally diverse origins and distinguished these from a panel of 12 other human com-
mensal and pathogenic mycoplasma species with 100% cross-validated statistical accu-
racy. Furthermore, PLS-DA correctly classified by strain type all 30 clinical isolates with
96% cross-validated accuracy for type 1 strains, 98% cross-validated accuracy for type 2
strains, and 90% cross-validated accuracy for type 2V strains.
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Introduction
The cell wall-less prokaryoteMycoplasma pneumoniae is a major cause of respiratory disease
in humans, accounting for 20% to 40% of all community acquired pneumonia (CAP).M. pneu-
moniae is the leading cause of CAP in older children and young adults, while the incidence of
infection in the very young and the elderly is on the rise [1–5]. For adults alone the annual eco-
nomic burden of CAP is> $17 billion [6]. Macrolide resistance is a growing concern, particu-
larly in children [5], and extra-pulmonary sequelae occur in up to 25% of infections. Finally,
evidence continues to indicate a contributing role forM. pneumoniae infection in the onset,
exacerbation, and recurrence of asthma [5].
An area of growing interest is the role ofM. pneumoniae strain type in pathogenesis and dis-
ease epidemiology. Genetic diversity is relatively limited amongM. pneumoniae strains, which
can be categorized into two major groups (type 1 or type 2) based on variation within sequence
of the P1 (MPN141) gene, although variant strains of the two are increasingly more common
[7]. The P1 protein is an important virulence factor and immunogen inM. pneumoniae infec-
tion [8–10]. P1 must complex with several other proteins in order to localize to the tip of the
terminal organelle, where it mediates receptor binding for attachment to the respiratory epithe-
lium, an essential step in successful colonization of the airways [9, 11]. Variation in the P1 gene
sequence is used to distinguish between type 1 and type 2 strains ofM. pneumoniae, but little is
known about phenotypic differences arising from this genetic variation. Perhaps notable in this
regard is the periodicity of type-switching that occurs between the two major genotypes in reg-
ular patterns of four to seven years [12].
M. pneumoniae infection is transmitted through aerosolized respiratory secretions and
spreads slowly but efficiently through close living quarters, with incubation periods up to
three weeks [13, 14]. Symptoms tend to be non-descript, often with complex and variable
clinical presentations, which makes definitive diagnosis challenging [2, 6, 15]. As a result,
diagnosis is often presumptive and relies heavily on the combination of physical findings and
the elimination of other possible causes [4, 5, 14]. The success rate for laboratory culture is
poor, even for experienced labs, while serologic testing, historically considered the foundation
for diagnosis ofM. pneumoniae infection, has limited sensitivity and specificity, a high ten-
dency for false-negatives, requires paired sera resulting in retrospective diagnosis, and must
often be paired with another diagnostic method [2, 4, 5, 10, 14]. Of the currently existing
alternatives, the most efficient means for detection is quantitative polymerase chain reaction
(qPCR). At present, the only FDA-approved tests for the clinical detection ofM. pneumoniae
are the Illumigene automated detection system (Meridian Bioscience, Inc., Cincinatti, Ohio)
and the FilmArray Respiratory Panel (BioFire Diagnostics Inc., Salt Lake City, Utah). The
Illumigene platform uses loop-mediated isothermal amplification and is capable of detecting
M. pneumoniae in both throat and nasopharyngeal swab specimens with a high degree of sen-
sitivity and specificity. The FilmArray Respiratory Panel employs nested, multiplex qPCR
with endpoint melt curve analysis on nasopharyngeal swabs to test for 21 different viral and
bacterial respiratory pathogens, and is capable of detectingM. pneumoniae as low as 30 col-
ony-forming units (CFU)/ml [16]. The current standard forM. pneumoniae genotyping is
PCR-restriction fragment length polymorphism, but can also be done by nested PCR and
sequencing, multilocus variable-number tandem-repeat analysis, or by qPCR and high resolu-
tion melt curve analysis [15, 17–19]. These methods for detection and genotyping exhibit
high sensitivity and specificity for all known strain variants, can allow for detection in the
early stages of infection, and can be performed in hospitals and reference laboratories [2, 4,
5]. However, the requirement for separate tests for detection and genotyping, as well as the
cost, complexity, and expertise required, limits the practicality for widespread, point-of-care
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use [2, 4–6, 14]. These limitations create a critical barrier to the accurate and timely diagnosis
ofM. pneumoniae infection and epidemiological tracking, and a rapid, simple, diagnostic
platform capable of simultaneous detection and genotyping would greatly improve the con-
trol ofM. pneumoniae disease.
Vibrational spectroscopy has an inherent biochemical specificity that led to its consider-
ation as a next-generation platform for the rapid detection, characterization, and identifica-
tion of infectious agents [20–23]. Raman spectroscopy in particular has several advantages for
application to biological samples, including narrow bandwidths, good spatial resolution, and
the ability to analyze aqueous samples due to the absence of interference by water molecules
[20, 21, 24]. Furthermore, Raman spectra provide detailed structural information on the
chemical composition of a sample and can serve as a characteristic molecular fingerprint for
pathogen identification [23, 24]. Despite these advantages, standard Raman spectra are inher-
ently limited by weak signals for detection. As a result, the application of traditional Raman
spectroscopy for biosensing applications was impractical and inefficient [13, 21, 24] until the
discovery that sample adsorption onto nanoscopically roughened metallic surfaces results in
significant enhancements in Raman signal and spectral intensity [23–25]. This enhancement,
by factors up to 1014-fold, is attributed to the increased electromagnetic field for molecules in
close proximity to the metallic surface [20, 21]. Surface-enhanced Raman spectroscopy
(SERS) retains the advantages of standard Raman spectroscopy, in addition to markedly
improved sensitivity, allowing for considerable success at whole organism molecular finger-
printing [20, 24, 26, 27].
Inconsistency and lack of reproducibility in the preparation of SERS-active substrates has
hindered its widespread use for biosensing applications [20, 21, 24]. However, highly ordered
silver nanorod array (NA) substrates fabricated using oblique angle deposition (OAD) yield
consistent SERS enhancement factors of around 108, with less than 15% variation between sub-
strate batches [21]. The reproducibility of NA-SERS substrates can be improved further when
patterned into a multiwell format with polydimethylsiloxane (PDMS) [20]. The highly repro-
ducible detection capabilities of NA-SERS have been well demonstrated for multiple infectious
agents, including RSV, rotavirus, influenza, HIV, adenovirus, SARS coronavirus, andM. pneu-
moniae [13, 22, 28–30].
Hennigan et al. described an NA-SERS-based platform capable of detectingM. pneumoniae
with statistically significant sensitivity and specificity in both simulated and true clinical throat
swabs, with the potential to detect and typeM. pneumoniae within a single test [13]. We
recently determined the sensitivity of NA-SERS forM. pneumoniae detection to be< 1 genome
equivalent (cell/μl) qualitatively, and to have a quantitative multivariate detection limit of
5.3 ± 1 cells/μl [31]. Initial evaluation of this biosensing platform’s capabilities indicates the
potential for application as a next-generation diagnostic tool for the clinical detection ofM.
pneumoniae, but a more comprehensive analysis is needed prior to proceeding with clinical
validation. In the present study we further explored the specificity of NA-SERS forM. pneumo-
niae detection with a panel of 30M. pneumoniae isolates collected from representative global
outbreaks and spanning clinically relevant genotypes. Furthermore, since NA-SERS has inher-
ent biochemical specificity, we analyzed a panel of 12 other human commensal and pathogenic
mycoplasmas to demonstrate that this biosensing platform could distinguishM. pneumoniae
from its clinically relevant closest phylogenetic relatives. Finally, we evaluated the ability of the
NA-SERS platform to correctly type the 30M. pneumoniae clinical isolates relative to known
reference strains ofM. pneumoniae.
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Methods
Preparation ofM. pneumoniae controls and clinical isolates for SERS
analysis
Wild typeM. pneumoniae reference strains M129 (type 1) and FH (type 2) were grown, har-
vested, and prepared at the University of Georgia (UGA) for this study. A panel of 30 addi-
tional clinical isolates consisting of 13 type 1 strains, 11 type 2 strains, and six type 2 variant
strains were grown, harvested, and prepared for SERS and quality control analysis at the Pneu-
monia Response and Surveillance Laboratory at the Centers for Disease Control and Preven-
tion (CDC) in Atlanta, Georgia. P1 genotype groups were determined by the Pneumonia
Response and Surveillance Laboratory at the CDC in Atlanta, GA using DNA sequence analy-
sis, qPCR in combination with high resolution melt curve analysis, and RFLP sequencing anal-
ysis. All mycoplasma isolates and controls were cultured in SP4 medium [2, 30] in tissue
culture flasks with a 1μl/ml inoculation and incubated at 37°C. Strains grown at UGA were har-
vested at log phase when the phenol red indicator turned an orange color upon reaching a pH
of ~6.5. Strains grown at the CDC were harvested 14 days from the date of inoculation to
ensure adequate growth for all isolates. At time of harvest, the spent growth medium was
decanted for each flask and 0.1× volume of sterile PBS (pH 7.2) was added to wash the adherent
mycoplasmas. The PBS wash was then decanted and the PBS wash repeated 3× before the cells
were scraped into 1 ml sterile PBS. Cells were then syringe-passaged 10× with a 25 gauge needle
and aliquots made for determination of protein content, plating on PPLO agar [32] for CFU
determination (for select isolates and controls), DNA extraction for genome equivalent deter-
mination, and SERS analysis.
M. pneumoniae samples for SERS analysis were syringe-passaged 10× with a 25-gauge nee-
dle to disperse clumps, fixed with the addition of one volume of 8% formaldehyde in sterile
PBS (pH 7.0), and stored at 4°C. Growth medium negative control samples were prepared in
parallel under the same conditions as theM. pneumoniae reference strains as described previ-
ously [31]. At the time of SERS analysis, mycoplasma and medium-only negative control sam-
ples were diluted in sterile DI water to a concentration of 105 cells/μl, which falls within the
SERS detectable range forM. pneumoniae and was found to be dilute enough to ensure that the
spectra adequately represent SERS Raman spectra arising from the Ag nanorod substrate [31].
Samples were loaded onto the NA-SERS substrate immediately following this dilution.
Preparation of non-M. pneumoniae human commensal and pathogenic
species for NA-SERS analysis
Twelve human commensal and pathogenicMollicutes species closely related [33] toM. pneu-
moniae were grown and harvested at the University of Alabama at Birmingham (UAB). These
included: Acholeplasma laidlawii (ATCC 23206),Mycoplasma amphoriforme (A39 M6123;
provided by M. Balish, Miami University of Ohio),Mycoplasma fermentans (ATCC 19989),
Mycoplasma genitalium (ATCC 49897),Mycoplasma hominis (ATCCMh132),Mycoplasma
orale (ATCC 23714),Mycoplasma penetrans (UAB reference strain collection, year 1995),
Mycoplasma pirum (ATCC 25960),Mycoplasma salivarium (ATCC 23064),Mycoplasma sper-
matophilum (ATCC 49695), Ureaplasma parvum (Up1; ATCC 27813), and Ureaplasma urea-
lyticum (Uu11; ATCC 33695).Mycoplasma buccale,Mycoplasma lipophilum, andMycoplasma
faucium were originally intended to be included in the panel, but attempts at culturing these
organisms were unsuccessful. For each culture, 500 μl to 1 ml of stock culture was inoculated
into approximately 30 ml of SP4, Hayflick’s, or 10B depending on the individual species’
growth requirements, and incubated until the pH indicator changed color, indicative of
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microbial growth and utilization of the metabolic substrate in the media, i.e., glucose, arginine,
or urea. At the time of harvest the cells and spent media were poured into 50 ml polycarbonate
tubes and centrifuged at 8,000 RPM for 15 min, except for Ureaplasma species, which were
centrifuged for 1 hr. The supernatants were decanted and the pellets suspended in 30 ml sterile
PBS. The cells were washed by centrifugation at 8,000 RPM for 15 min as above, or 10,000
RPM for 1 hr for Ureaplasma species. The supernatants were then decanted and the pellets sus-
pended in 1 ml sterile PBS, transferred to a 1.5 ml vial, and centrifuged at 14,000 RPM for
20 min. The supernatants were again decanted and the pellets suspended in 1 ml sterile PBS
and syringe-passaged using a 26-gauge needle to disperse clumps. Aliquots were made for spot-
ting onto a blood agar plate to test for contamination, and plating for CFU and color-changing
unit (CCU) determination. Two 400 μl aliquots for each were centrifuged at 14,000 RPM for
20 min, the supernatant was removed, and the pellets were frozen for shipment to UGA, where
they were stored at -80°C.
For SERS and quality control analysis, cell pellets were suspended in 1 ml sterile PBS (pH
7.2) and syringe-passaged 10× with a 25 gauge needle to disperse clumps. Aliquots were then
made for DNA extraction and genome equivalent determination, protein assay, and NA-SERS
analysis. SERS samples were prepared by fixing 500 μl of suspended cells with 500 μl of 8%
formaldehyde in sterile PBS (pH 7.0), and stored at 4°C until time of SERS analysis. At that
time the samples were diluted in sterile DI water to a concentration of 103 to 104 cells/μl and
then immediately loaded onto the NA-SERS substrate. A growth medium only negative
control andM. pneumoniae strain M129 samples were prepared as described above for
comparison.
Preparation of samples for determination of protein content and genome
equivalents
All samples were analyzed for protein content via the Bicinchoninic acid assay [34]. DNA was
extracted by the QIAamp DNA Blood Minikit (Qiagen, Valencia, CA) using the blood and
body fluids protocol, including RNase A treatment. 200 μl of sample were used for DNA
extraction, with a final elution volume of 200 μl for use to quantify DNA content and genome
equivalents. Genomic DNA concentration and absorbance measurements for the Bicinchoni-
nic acid assay were performed on a NanoDrop instrument (Model ND-1000, Thermo Scien-
tific, Wilmington, DE) using software V3.5.2. Genome equivalents ofM. pneumoniae samples
were calculated from the DNA concentration obtained from this analysis and using the previ-
ously determined mass of theM. pneumoniae genome, 5.3x107 Daltons [35]. Genome equiva-
lents for all non-M. pneumoniae samples were determined from DNA concentrations obtained
from this analysis and a genome mass calculated for this study based on published genome
lengths and known G+C contents from the GenBank database.
NA-SERS and chemometric analysis
NA-SERS substrates were prepared by OAD as described [21, 29, 36, 37]. Prior to their use,
substrates were cleaned for 5 min in an Ar+ plasma using a plasma cleaner (Model PDC-32G,
Harrick Plasma, Ithaca, NY) to remove any surface contamination [38] and then patterned
into 40 3mm diameter PDMS-formed wells. 1,2-bis(4-pyridyl)ethylene (BPE; 10-4 Molar in
methanol) was used as an external control to ensure consistency between substrates. Raman
spectra were acquired using a Renishaw inVia Reflex multi-wavelength confocal imaging
microscope (Hoffman Estates, IL). A Leicha apochromatic 5× objective (NA 0.12) illuminated
a 1265 μm2 area on the substrate, which allows spatial averaging and minimizes the effect of
potential random hot spots. A 785-nm near-infrared diode laser (Renishaw) operating at 10%
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power capacity (28 mW) provided the incoming radiation, and spectra were collected in 3
10-sec acquisitions. An internal silicon standard measurement was obtained at the beginning
of each SERS analysis as an internal control for instrument performance.
All samples were applied in duplicate to the NA substrates at the concentrations specified,
in a volume of 1 μl per well, and allowed to dry overnight. Spectra were collected from five ran-
dom locations within each sample spot for analysis, for a total of 10 spectra per sample, andM.
pneumoniae reference strain and growth medium controls were independently prepared and
analyzed for each substrate. Two wells per substrate were intentionally left blank to obtain a
background SERS reading on the naked nanorod substrate only. A total of three separate NA
substrates were used for these experiments: two for analysis ofM. pneumoniae isolates with
n = 390 spectra, and one for analysis of other human and commensalMollicutes species with
n = 150 spectra, resulting in a total of n = 540 spectra. Spectra were deliberately collected from
multiple locations within a single substrate, as well as from multiple substrates, to ensure any
inherent variance present in the substrates did not impact the results. Raman spectra between
400–1800 cm-1 were acquired using Renishaw’s WiRE 3.4 software. Instrument settings were
optimized to maximize signal and minimize saturation or sample degradation arising from
laser stimulation [13, 20].
Raman spectra were first averaged using GRAMS32/A1 spectral software package (Galactic
Industries, Nashua, NH) in order to assess signal-to-noise quality, and baseline-corrected
using a concave rubberband algorithm which performed 10 iterations on 64 points to aid in
preliminary evaluation of the spectra and peak assignment (OPUS, Bruker Optics, Inc., Biller-
ica, MA). Chemometric analysis was carried out with MATLAB version 7.10.0 (The Math-
works, Inc., Natick, MA) using PLS-Toolbox version 7.5.1 (Eigenvector Research Inc.,
Wenatchee, WA). Raw spectra were pre-processed using the 1st derivative of each spectrum
and a 15-point, 2nd order polynomial Savitsky-Golay algorithm. Each dataset was then vector-
normalized and mean-centered. Due to the inherently complex nature of spectral data, multi-
variate statistical analysis of the datasets was performed using principal component analysis
(PCA) and partial least squares-discriminatory analysis (PLS-DA), using the PLS
Toolbox software. Unless otherwise specified, all PLS-DA models were cross-validated using a
Venetian blinds algorithm with 10 data splits. All PLS-DA models in this study, excluding
those for individual sample analysis, were generated using between 110–495 total spectra per
model.
Results and Discussion
Detection ofM. pneumoniae clinical isolates
We analyzed 32 clinical isolates, including reference strains M129 (type 1) and FH (type 2),
alongside a growth medium control prepared in parallel with theM. pneumoniae samples. Full
details regarding isolate origin and year, P1 genotype, macrolide susceptibility, protein and
DNA content, and genome equivalents forM. pneumoniae strains are given in Table 1. CFU
values were determined for both reference strains and six randomly chosen additional isolates
to assess cell viability at time of fixation and ranged from 1x105 to 1x107 CFU/ml. Due to the
propensity for mycoplasma cells to clump, a confounding factor in using CFU values as a met-
ric for sample content is the potential discrepancy between CFU value and actual cell number,
which can differ by as much as 103-fold [39]. Therefore, protein content and genome equiva-
lents were determined in order to better define the content of the samples at the concentration
analyzed by SERS. These values fell within comparable ranges and were consistent with pub-
lished values for bacterial cells [40]. Protein concentration per cell was higher forM. pneumo-
niae isolates harvested during stationary phase relative to those harvested during log phase
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(growth phase based on the color of the pH indicator in the SP4 medium), but no notable dif-
ferences in genome equivalents or SERS spectra were observed betweenM. pneumoniae sam-
ples relative to growth phase at time of harvest (data not shown). Average SERS spectra of the
nanorod substrate background, growth medium control, andM. pneumoniae samples are
shown in Fig 1, with each class exhibiting a distinct band pattern, as expected.











fg of protein / cell
E1 Egypt 2009 2 S 0.149 2.0 4.49x106 26
E16 Egypt 2010 1 S 0.057 1.7 4.34x106 11
K3 Kenya 2010 2 S 0.065 2.3 6.5x106 10
K20 Kenya 2010 1 S 0.044 1.2 3.39x106 12.9
G6 Guatemala 2010 1 S 0.078 2.6 7.36x106 10.6
NM2 NM 2010 1 R 0.074 1.1 3.11x106 23.8
RI1 RI 2011 2 S 0.071 1.5 4.24x106 16.7
OR1 OR 2011 1 R 0.076 1.3 3.68x106 20.7
WV1 WV 2011 2 S 0.094 1.9 5.34x106 17.6
WV9 WV 2012 1 R 0.071 1.3 3.68x106 19.3
FL1 FL 2012 1 S 0.098 2.3 6.5x106 15
WI11 WI 2014 2V S 0.085 1.6 4.53x106 18.8
WI17 WI 2014 2V S 0.047 1.8 5.09x106 9.2
CO12 CO 2014 2V S 0.077 1.6 4.53x106 16.9
CO44 CO 2014 2V R 0.073 1.3 3.68x106 19.8
SA18 S. Africa 2013 2V S 0.35 1.7 4.81x106 72.8
SA19 S. Africa 2013 2 S 0.47 1.1 3.11x106 151.0
SA22 S. Africa 2013 1 S 0.44 1.1 3.11x106 141.5
1005 NY 1999 2 S 0.28 1.5 4.24x106 66.0
1134 IN 1999 2 S 0.30 2.2 6.22x106 70.8
988 Canada 1992 1 S 0.12 2.0 5.65x106 19.3
678 Denmark 1962 1 S 0.12 3.5 9.9x106 12.1
682 Denmark 1988 2 S 0.16 2.1 5.94x106 26.9
983 SC 1988 2 S 0.16 1.6 4.53x106 35.3
386 TX 1994 2 S 0.10 2.9 8.2x106 12.1
519 CA 1995 2 S 0.28 1.5 4.24x106 63.6
GA1 GA 2012 1 S 0.22 3.5 9.9x106 22.2
GA3 GA 2012 2V S 0.46 3.3 9.33x106 49.3
IL1 IL 2012 1 R 0.12 1.7 4.81x106 24.9
IL2 IL 2012 1 R 0.10 1.8 5.09x106 19.6
M129 N/A N/A 1 S 0.169 4.1 1.13x107 14
M129c N/A N/A 1 S 0.168 4.3 1.20x107 14
FH N/A N/A 2 S 0.046 2.1 5.94x106 7.7
FHc N/A N/A 2 S 0.046 2.2 6.30x106 7.3
a M. pneumoniae P1 genotype groups based upon DNA sequence analysis performed by the Pneumonia Response and Surveillance Laboratory at the
CDC in Atlanta, GA.
b S, susceptible; R, resistant
c Two independent preparations of M129 and FH were examined
N/A = information not available
doi:10.1371/journal.pone.0131831.t001
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PLS-DA was applied here to determine statistically significant detection ofM. pneumoniae
by NA-SERS. PLS-DA is a full-spectrum, multivariate, supervised statistical method whereby
prior knowledge of classes is used to yield more robust discrimination by minimizing variation
within classes while emphasizing latent variables arising from spectral differences between clas-
ses [41, 42]. A PLS-DA model was generated to discriminate between three classes: the nanorod
substrate background (Fig 2A); the growth medium control (Fig 2B); and allM. pneumoniae
strains (Fig 2C). The inclusion of substrate background and growth medium controls allowed
us to ensure that any differences in growth medium and nanorod background signal within the
substrate did not affect the ability of the model to discriminate between the presence or absence
ofM. pneumoniae. Two nanorod substrates were used for these experiments, with each con-
taining duplicate wells of the bare nanorod substrate, independently prepared M129, FH, and
growth medium controls, and 15 additional clinical isolates ofM. pneumoniae. A total of
n = 390 pre-processed NA-SERS spectra collected from both substrates were included in the
model, consisting of 20 nanorod substrate background spectra, 20 growth medium control
spectra, 25 M129 spectra, 25 FH spectra, and 10 spectra per additional clinical isolate. The
cross-validated statistics for the model show that NA-SERS correctly classified all 32 clinical
isolates asM. pneumoniae regardless of global origin, year isolated, genotype, or macrolide sus-
ceptibility phenotype, and distinguished them from the substrate background and the growth
medium control with 100% cross-validated sensitivity and specificity.
Fig 1. Averaged, baseline-corrected, and normalized SERS spectra for the nanorod substrate, growthmedium control, andM. pneumoniae
reference strain controls and clinical isolates, as indicated.Raw spectra of the three sample classes were averaged, baseline-corrected, and normalized
using GRAMS32/A1 spectral software package (Galactic Industries, Nashua, NH). For the nanorod substrate background class, n = 20; for the growth
medium control class, n = 20; and for theM. pneumoniae class, n = 350.
doi:10.1371/journal.pone.0131831.g001
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Fig 2. PLS-DA of 32M. pneumoniae clinical isolates, including reference strains M129 and FH. Each
panel represents a cross-validated class prediction score for (A) class 1, substrate background; (B) class 2,
growth medium control; and (C) class 3, allM. pneumoniae strains. For panels A-C, each individual shape
represents a single pre-processed NA-SERS spectrum. The substrate background spectra are represented
by gray diamonds, the growth medium control spectra by solid black squares, and theM. pneumoniae
spectra by open shapes that differ by cluster to indicate the different individual strains and isolates. The red-
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Differentiation ofM. pneumoniae and 12 other human commensal and
pathogenicMollicutes species
A critical question for clinical detection platforms is specificity for the pathogen of interest,
particularly in the context of other organisms potentially present in a clinical sample. SERS is a
structure-based technique that generates a Raman fingerprint or barcode based on the unique
molecular content of the sample, and as such, the most likely organisms to generate false posi-
tives would be those most closely resemblingM. pneumoniae structurally. To evaluate the spec-
ificity of the NA-SERS biosensing platform, 12 human commensal and pathogenicMollicutes
species closely related toM. pneumoniae in rpoB β-subunit nucleotide and amino acid
sequence phylogenies and 16S rDNA phylogeny were chosen for analysis alongsideM. pneu-
moniae strain M129 and a growth medium control [33]. In order to best define the content of
the sample at the concentration used for SERS, analyses were done to determine total protein
and DNA content, the latter allowing calculation of genome equivalents based on known
genome sizes and G+C content (Table 2). These fell within comparable ranges and were consis-
tent with published values for bacterial cells [40].
Our goal here was to develop a PLS-DA model that distinguishedM. pneumoniae from a
panel of closely-related otherMollicutes species that might be found in humans. A total of
n = 150 pre-processed NA-SERS spectra were collected on a single nanorod substrate consist-
ing of n = 10 substrate background spectra, n = 10 growth medium control spectra, n = 10M.
pneumoniae spectra, and 10 spectra each per otherMollicutes species. An initial PLS-DA
model was generated to discriminate between two classes, the nanorod substrate background
and all other biological samples, which it did with 100% cross-validated sensitivity and
dotted line indicates the classification threshold line for positive class prediction, and the black-dotted line
indicates the 95% confidence interval. Cross-validated sensitivity, specificity, and class error for the panels
were as follows: (A) nanorod substrate background: 1.00, 1.00, and 0, respectively; for (B) growth medium
control: 1.00, 1.00, and 0, respectively; and for (C)M. pneumoniae: 1.00, 1.00, and 0, respectively. Cross-
validated statistics were obtained using Venetian blinds with 10 data splits to represent the prediction
performance of the PLS-DAmodel forM. pneumoniae detection.
doi:10.1371/journal.pone.0131831.g002










Acholeplasma laidlawii 1,496,992 0.247 16.2 1.9x106 130 4.55x105
Mycoplasma amphoriforme 1,029,022 0.072 2.4 4.3x105 167 ND
Mycoplasma fermentans 1,118,751 0.374 23.8 3.9x106 95.9 2.6x106
Mycoplasma genitalium 580,073 0.099 2.6 8.2x105 121 1.75x104
Mycoplasma hominis 665,445 0.454 10.7 2.9x106 157 2.2x105
Mycoplasma orale 710,549 0.114 8.1 2.1x106 54.3 9.9x104
Mycoplasma penetrans 1,358,633 0.813 19 2.6x106 313 1.7x106
Mycoplasma pirum 510,593 0.384 20 7.2x106 53.3 3.85x106
Mycoplasma salivarium 710,000 0.558 32.1 8.32x106 67.1 1x105
Mycoplasma spermatophilum 846,000 0.068 1.2 2.6x105 261 ND
Ureaplasma parvum 727,289 0.068 1.7 4.3x105 158 4.5x104
Ureaplasma urealyticum 874,478 0.067 2 4.2x105 159 5.6x103
Mycoplasma pneumoniae 816,394 0.061 1 2.24x106 27.2 8.4x104
aGenome sizes obtained from published sources [35] and known G+C contents from the GenBank database
doi:10.1371/journal.pone.0131831.t002
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specificity (data not shown). The purpose of this model was to ensure that the nanorod sub-
strate background signal was significantly different than all other samples in order to exclude
the background spectra from our future models. Once we determined that the nanorod sub-
strate background class could be excluded, a second PLS-DA model was generated using the
same spectra to distinguish among three classes; the growth medium control,M. pneumoniae,
and the otherMollicutes species. This model had a total of n = 140 pre-processed NA-SERS
spectra, consisting of n = 10 growth medium control spectra, n = 10M. pneumoniae spectra,
and 10 spectra each per otherMollicutes species. This model distinguished the three classes
with 100% cross-validated sensitivity and specificity (data not shown). Upon the successful
development of a PLS-DA model to distinguish between the growth medium control,M. pneu-
moniae, and all otherMollicutes species, a final PLS-DA model was generated using pre-pro-
cessed NA-SERS spectra from all three nanorod substrates analyzed during these experiments.
This model contained a total of n = 495 spectra, consisting of 25 growth medium control spec-
tra, 25 M129 spectra, 25 FH spectra, 10 spectra each per otherM. pneumoniae clinical isolates
(30 isolates total), and 10 spectra each per otherMollicutes species (12 species total). This
model was also categorized into three classes: the growth medium control (Fig 3A); allM.
pneumoniae clinical isolates, including reference strains (Fig 3B); and all otherMollicutes spe-
cies (Fig 3C). PLS-DA distinguished allM. pneumoniae strains from all 12 other humanMolli-
cutes species and the growth medium control with 100% cross-validated sensitivity and
specificity (Fig 3A–3C).
M. pneumoniae typing capabilities of NA-SERS
A key advantage of NA-SERS for biosensing is the potential to detect and type an organism in
a single test, especially of interest here since there is currently no existing platform capable of
the simultaneous detection and typing ofM. pneumoniae. To evaluate this capability we
applied PLS-DA to theM. pneumoniae strain spectra above. Our panel of clinical isolates con-
tained three distinct and clinically relevant genotypes ofM. pneumoniae: 13 type 1 strains, 11
type 2 strains, and six type 2 variant (2V) strains.M. pneumoniae strains M129 (type 1) and
FH (type 2) were used as reference strain controls, as they have been previously applied in this
manner for evaluation ofM. pneumoniae genotyping assays [19].
For the type 1 strains a PLS-DA model was generated using 180 pre-processed NA-SERS
spectra consisting of the 25 M129 spectra and the 25 FH spectra as controls, and all spectra
from the 13 other type 1 clinical isolate samples (10 spectra per isolate, 130 total spectra). The
model was built to discriminate between 2 classes, either type 1 or type 2. PLS-DA was able to
correctly classify all other 13 type 1 strains with the type 1 reference strain with 96.8% sensitiv-
ity and 96% specificity (Fig 4A). For the type 2 strains a second PLS-DA model was generated
using 160 pre-processed NA-SERS spectra consisting of the 50 type 1 and 2 reference strain
control spectra and all spectra from the 11 other type 2 clinical isolate samples (10 spectra per
isolate, 110 total spectra). This model was likewise built to discriminate between 2 classes,
either type 1 or type 2. PLS-DA was able to correctly classify all 11 other type 2 isolates with the
type 2 reference strain control with 99.3% sensitivity and 100% specificity (Fig 4B).
For type 2V clinical isolates, a third PLS-DA model was generated using 110 pre-processed
NA-SERS spectra consisting of the 50 type 1 and 2 reference strain control spectra and all spec-
tra from the type 2V clinical isolate samples (10 spectra per isolate, 110 total spectra). However,
this model was built to discriminate between 3 classes, type 1 reference strain control, type 2
reference strain control, or type 2V clinical isolate spectra. A third class was necessary for clas-
sification of this genotype, as existing methods are capable of identifying variant strains as
unique from type 1 and 2 isolate strains [18], and as such for clinical purposes NA-SERS typing
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Fig 3. PLS-DA distinguishingM. pneumoniae strains from other human commensal and pathogenic
Mollicutes species. Each panel represents a cross-validated class prediction score for (A) class 1, growth
medium control; (B) class 2, allM. pneumoniae strains; and (C) class 3, all other human commensal and
pathogenicMollicutes samples. For panels A-C, each individual shape represents a single pre-processed
NA-SERS spectrum. The growth medium control spectra are represented by gray diamonds, theM.
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should be able to do the same. PLS-DA correctly classified the type 1 reference strain control as
distinct from the type 2 control and the type 2V clinical isolates with 100% cross-validated sen-
sitivity and 98.8% cross-validated specificity (Fig 5A). Furthermore, PLS-DA distinguished the
type 2 reference strain control from the type 1 control and 2V clinical isolates with a cross-
validated sensitivity and specificity of 92% and 90.6%, respectively (Fig 5B). Lastly, PLS-DA
correctly classified all six type 2V strains as distinct from the type 1 and 2 reference strain con-
trols with 100% cross-validated sensitivity and specificity (Fig 5C). The drop in sensitivity and
specificity observed for the type 2 reference strain control is likely due to the fact that these are
variant strains of the type 2 parent strain, and variant strains tend to be more similar to their
respective parent strains genetically than either are to the opposite strain type [18, 37].
To further evaluate the strain typing capabilities of NA-SERS, PLS-DA models were gener-
ated using the M129 and FH reference strains alongside each clinical isolate individually.
Thirty PLS-DA models were built using the 25 type 1 M129 spectra and 25 type 2 FH spectra
as reference strain control classes, and 10 clinical isolate spectra treated as an unknown class.
For type 1 and 2 clinical isolates, two categories were used for cross-validation of the model,
while for type 2V isolate strains, three categories were incorporated to cross-validate the
model, as described above. For all clinical isolate types the model was cross-validated by using
a Venetian blinds algorithm with seven data splits. These PLS-DA models were incorporated
to simulate a potential strategy for future application of NA-SERS forM. pneumoniae genotyp-
ing wherein known strain type controls are used to predict the genotype of an unknown clinical
sample. Full cross-validated statistics for all 30 PLS-DA models are given in Table 3 for all type
1 and 2 clinical isolates, and Table 4 for all type 2V clinical isolates. Overall, PLS-DA perfor-
mance was consistent with the models shown in Figs 4 and 5. The only notable difference in
performance was a decrease in cross-validated specificity in the individual modeling for type 1
clinical isolates K20, NM2, and FL1, but this likely arises due to the decreased sample size
(n = 60) used to build the individual PLS-DA models.
Additionally, we compared averaged, baseline-corrected, and normalized spectra of all three
genotypes to look for any differences in band pattern between the three genotypes that could
be contributing to the classification capabilities demonstrated in the PLS-DA modeling (Fig 6).
The majority of the spectral fingerprint was identical for all three strain types, which is to be
expected since they are all the same species and classify as such in the PLS-DA models shown
in Figs 2 and 3. However, several visible differences in band pattern were present in the spectra
for each genotype ofM. pneumoniae, which could account for the ability of NA-SERS to distin-
guish between the three genotypes with statistically significant sensitivity and specificity. The
averaged type 1 spectrum had two unique peaks, one at 1636 cm-1 that does not appear in the
averaged type 2 or 2V spectra, and one at 959 cm-1 which appeared as more distinct and shifted
slightly right in the type 1 spectrum when compared to the type 2 spectrum, and did not appear
in the type 2V spectrum. The averaged type 2 strain spectrum was very similar to the type 1
strain spectrum aside from the differences mentioned above and the presence of a doublet at
767 and 778 cm-1, which appeared as more distinct than that present in the type 2V spectrum
pneumoniae spectra by open shapes that differ by cluster to indicate the different individual strains and
isolates, and the human commensal and pathogenicMollicutes species are represented by light gray shapes
that differ by cluster to indicate the individual species. The red-dotted line indicates the classification
threshold line for positive class prediction, and the black-dotted line indicates the 95% confidence interval.
Cross-validated sensitivity, specificity, and class error for the panels were as follows: (A) growth medium
control: 1.00, 1.00, and 0, respectively; for (B) AllM. pneumoniae samples: 1.00, 1.00, and 0, respectively;
and for (C) All 12Mollicutes species: 1.00, 1.00, and 0, respectively. Cross-validated statistics were obtained
using Venetian blinds with 10 data splits to represent the prediction performance of the PLS-DAmodel forM.
pneumoniae detection.
doi:10.1371/journal.pone.0131831.g003
Mycoplasma Detection by NA-SERS
PLOSONE | DOI:10.1371/journal.pone.0131831 June 29, 2015 13 / 24
Fig 4. PLS-DA for NA-SERS typing of type 1 and 2M. pneumoniae strains.Cross-validated class prediction scores for (A) all 13 type 1 clinical isolates,
and (B) all 11 type 2 clinical isolates. For panels A and B, each individual shape represents a single pre-processed NA-SERS spectrum.M. pneumoniae type
1 reference strain control and other clinical isolates are represented by dark gray diamonds, while the type 2 reference strain control and other clinical
isolates are represented by open shapes. Shapes differ by cluster to indicate the individual clinical isolates and samples, and the strain/isolate designation is
indicated above the brackets for each cluster. The red-dotted line indicates the classification threshold line for positive class prediction, and the black-dotted
line indicates the 95% confidence interval. The cross-validated sensitivity, specificity and class error were obtained using Venetian blinds with 10 data splits
to represent the prediction performance of models for classification of (A) type 1 strains: 0.968, 0.96, and 0.04, respectively and for (B) type 2 strains: 1.00,
0.993, and 0.004, respectively.
doi:10.1371/journal.pone.0131831.g004
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Fig 5. PLS-DA for NA-SERS typing of type 2VM. pneumoniae clinical isolates.Cross-validated class
prediction scores for (A) class 1, the type 1 reference strain control; (B) class 2, the type 2 reference strain
control; and (C) class 3, all six type 2V clinical isolates. For the panels A-C, each individual shape represents
a single pre-processed NA-SERS spectrum. TheM. pneumoniae type 1 reference strain control is
represented by dark gray diamonds, the type 2 reference strain control is represented by open squares, and
the type 2V clinical isolates are represented by light gray shapes. The light gray shapes differ by cluster to
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and as a broad singlet in the type 1 spectrum. The averaged type 2V spectrum appeared to be
the most distinct of the three, with a doublet at 875 and 890 cm-1 that appeared as a single peak
at 890 in type 1 and 2 spectra, and a small peak at 521 that was also absent in type 1 and 2 spec-
tra. While these spectral differences were extremely subtle, chemometric analysis is highly
capable of discerning differences such as these with substantial discriminatory classification
power [43].
Although little is known about the phenotypic effects of strain type beyond observable dif-
ferences in biofilm formation [44], the genotypic differences between them are well character-
ized. Briefly, homologous recombination within the p1 gene of repetitive element sequences
located both in and outside the p1 gene contributes to sequence variation between strain types
indicate the individual clinical isolates, and the strain/isolate designation is indicated above the brackets for
each cluster. The red-dotted line indicates the classification threshold line for positive class prediction, and
the black-dotted line indicates the 95% confidence interval. The cross-validated sensitivity, specificity and
class error for panels A-C were obtained using Venetian blinds with 10 data splits to represent the prediction
performance of (A) type 1 strains: 1.00, 0.988, and 0.006, respectively; for (B) type 2 strains: 0.92, 0.906, and
0.08, respectively; and for (C) type 2V strains: 1.00, 1.00, and 0, respectively.
doi:10.1371/journal.pone.0131831.g005
Table 3. Cross-validated PLS-DAmodeling statistics for the prediction performance for NA-SERS typing of individual type 1 and 2M. pneumoniae
clinical isolates.
Isolate P1 Type CV Sensitivity CV Specificity CV Class Error
E16 1 0.943 0.92 0.06
K20 1 1 0.84 0.08
G6 1 1 0.92 0.04
NM2 1 1 0.88 0.06
OR1 1 0.914 0.92 0.08
WV9 1 0.914 0.96 0.06
FL1 1 0.971 0.84 0.09
SA22 1 0.971 1 0.01
988 1 0.971 1 0.01
678 1 1 1 0
GA1 1 1 1 0
IL1 1 1 1 0
IL2 1 0.971 1 0
E1 2 1 0.971 0.01
K3 2 1 1 0
RI1 2 1 1 0
WV1 2 1 1 0
SA19 2 1 1 0
1005 2 1 1 0
1134 2 1 0.971 0.01
682 2 1 1 0
983 2 1 1 0
386 2 1 1 0
519 2 1 1 0
Two categories were used for cross-validation of the model, either type 1 or type 2. Clinical isolates were treated as an unknown class and cross-validated
sensitivity, specificity, and class error were based on their classification prediction score with their respective reference strain control class. CV, cross-
validated.
doi:10.1371/journal.pone.0131831.t003
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[7]. Nucleotide and amino acid sequencing of 60M. pneumoniae isolates indicates that trinu-
cleotide short sequence repeats (SSR’s) coding for serine can be found in all strain types any-
where from 5–14 times, but appear to be most prevalent in type 1 strains [7]. Serine repeats
may form a hinge structure and lead to downstream conformational differences in the P1 pro-
tein between the different strain types, which could potentially affect its interaction with the
host as a surface antigen [45, 46]. In addition, 14 of the 60 isolates in the Zhao et al. study had
point mutations in several variant strains corresponding to amino acid changes in P1 to gluta-
mine, proline, asparagine, and isoleucine residues [7].
In our study, the peaks unique to the type 1 spectrum are commonly associated with vibra-
tional mode bonds present in lysine (959 cm-1) and amide I or alpha helix (1636 cm-1) molecular
structures [47–49]. The peaks unique to the type 2 spectral fingerprint located at 767 and 778
cm-1 are commonly associated with vibrational modes found in histidine, tryptophan, or carbo-
hydrate bonds [48–50]. Finally, the peaks unique to the type 2V clinical isolates found at 521,
875 and 890 cm-1 are frequently associated with bonds present in histidine, tryptophan,
ribose, indole, asparagine, methionine, glutamine, and S-S and C-C stretching vibrational
modes [48–50]. Interestingly, the unique peaks present in the average spectra for the strain
types analyzed in this study are predominately associated with protein backbone, amino acid
residue, and DNA bond vibrations. Furthermore, spectral features in the averaged spectrum
of the 2V variant strains are consistent with the point mutations identified in the Zhao et al.
study [7], and our overall spectral interpretation of the averaged spectra for each strain type is
consistent with what is known about the differences between strain types ofM. pneumoniae
infection.
Table 4. Cross-validated PLS-DAmodeling statistics for the prediction performance for NA-SERS typing of individual type 2VM. pneumoniae clin-
ical isolates.
Isolate P1 Type CV Sensitivity CV Specificity CV Class Error
1: M129 1 1 0.971 0.01
2: FH 2 0.8 0.943 0.13
3: WI11 2V 1 0.98 0.01
1: M129 1 1 1 0
2: FH 2 0.88 0.943 0.08
3: WI17 2V 1 0.98 0.01
1: M129 1 1 0.971 0.01
2: FH 2 0.84 1 0.08
3: CO12 2V 1 1 0
1: M129 1 1 1 0
2: FH 2 0.92 0.971 0.05
3: CO44 2V 1 0.98 0.01
1: M129 1 1 1 0
2: FH 2 1 0.943 0.03
3: SA18 2V 1 1 0
1: M129 1 1 1 0
2: FH 2 0.96 1 0.02
3: GA3 2V 1 1 0
Three categories were incorporated to cross-validate the model: either type 1; type 2; or neither. Clinical isolates were treated as an unknown class and
cross-validated sensitivity, specificity, and class error were based on their classification prediction score as neither type 1 or type 2 reference control
strains (i.e. category 3).
doi:10.1371/journal.pone.0131831.t004
Mycoplasma Detection by NA-SERS
PLOSONE | DOI:10.1371/journal.pone.0131831 June 29, 2015 17 / 24
Unsupervised chemometric analysis ofM. pneumoniae strain types and
Mollicutes species
We applied PCA to supplement the PLS-DA modeling of sample spectra and evaluate the total
variance present in ourM. pneumoniae typing and other human commensal and pathogenic
Mollicutes datasets. PCA is an unsupervised form of chemometric analysis which reduces the
dimensionality of the dataset and facilitates establishing patterns and grouping of similar spec-
tra without a priori knowledge of sample class [43]. PCA explains successively smaller propor-
tions of the variance, with the first few principal components explaining the greatest
percentage of total variance present in the dataset [51].
Pre-processed SERS spectra fromM. pneumoniae reference strain type 1 and 2 controls and
all other type 1 clinical isolates were used to generate a PCA plot comparing principle compo-
nents 1, 2, and 3, which captured 54.3% of the total variance present in the 180 spectra used to
build the model (Fig 7A). Type 2 control strain FH clustered in the bottom right corner, and
the clustering pattern for all type 1 strains was predominately below and to the left, though
some overlap between the two strain types was present. The PCA model of the type 1 clinical
isolates supports the PLS-DA modeling of the spectra shown in Fig 4A.
Fig 6. Comparison of averaged, baseline-corrected, and normalized SERS spectra for type 1, type 2, and type 2V genotypes. Raw spectra of all type
1 (n = 155), type 2 (n = 135), and type 2V (n = 60) clinical isolates and controls were averaged, baseline-corrected, and normalized using GRAMS32/A1
spectral software package (Galactic Industries, Nashua, NH). Red, average spectrum of all type 1M. pneumoniae strains; green, average spectrum of all
type 2M. pneumoniae strains; blue, average spectrum of all type 2VM. pneumoniae strains. Peaks unique to a specific genotype ofM. pneumoniae are
indicated by arrows and identified above the spectral fingerprint. Type 1 peaks, red arrows; type 2 peaks, green arrows; and type 2V peaks, blue arrows.
Inset at top right of image depicts zoomed-in view of the type 2 doublet at 767 and 778 cm-1.
doi:10.1371/journal.pone.0131831.g006
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A second PCA model was built using pre-processed SERS spectra (n = 160) consisting of
type 1 and 2 reference strain controls and all other type 2 clinical isolates ofM. pneumoniae.
Principal components 1–3 captured 58.0% of the total variance and when plotted orthogonally
showed a distinct separation between the type 1 reference strain control and all type 2 reference
strain and other isolates, with very little overlap of clusters (Fig 7B). PCA modeling for the type
2 clinical isolate dataset was consistent with the PLS-DA modeling of the data shown in Fig 4B.
A third PCAmodel was built using the pre-processed SERS spectra from the type 2V clinical
isolate dataset (n = 110). Principal components 1–3 captured 54.1% of the total variance and
when plotted orthogonally showed distinctly separated clusters for the type 1 control, the type
2 control, and the type 2V clinical isolates, with some overlap present between the type 2 and
Fig 7. Principle component analysis ofM. pneumoniae strain typing and other human commensal and pathogenicMollicutes species. For all
panels, each individual shape represents a single sample spectrum. PC scores plots of 1 vs. 2 vs. 3 of: (A)M. pneumoniae reference strains and all 13 other
type 1 clinical isolates; (B)M. pneumoniae reference strains and all 11 other type 2 clinical isolates; (C)M. pneumoniae type 1 reference strain, type 2
reference strain, and all six type 2V clinical isolates; and (D) growth medium control, allM. pneumoniae strains, and all 12 other human commensal and
pathogenicMollicutes species. For panels A-C, dark gray diamonds represent type 1 sample spectra whereas open squares represent the type 2 sample
spectra. In panel C, type 2V clinical isolate spectra are represented by light gray triangles. For panel D, growth medium control spectra are represented by
dark gray diamonds,M. pneumoniae spectra by open squares, and all 12 otherMollicutes species by light gray triangles. For panels A-D, clustering of
samples is indicated by black circles or brackets.
doi:10.1371/journal.pone.0131831.g007
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type 2V clusters (Fig 7C). This clustering pattern further supports the PLS-DA classification
performance shown in Fig 5.
Finally, a PCA model was built using the fullM. pneumoniae andMollicutes species dataset
consisting of pre-processed spectra from all 3 nanorod array substrates (n = 495). Principal
components 1–3 captured 50.1% of the total variance and when plotted orthogonally showed
three distinctly separated clusters for growth medium control spectra, allM. pneumoniae spec-
tra, and all otherMollicutes species spectra, with no overlap between clusters (Fig 7D). This
supports the PLS-DA model of the data shown in Fig 3.
Species-level discrimination by NA-SERS
Our final question of interest was the ability of the platform to discriminate among the 13 dif-
ferent species analyzed in this study. However, PLS-DA classification performance diminishes
as the number of classes in question increases, due to the underlying algorithms applied by the
Table 5. Cross-validated PLS-DAmodeling statistics for the prediction performance for species discrimination betweenM. pneumoniae and nine
other human commensal and pathogenicmycoplasma species individually.
Isolate CV Sensitivity CV Specificity CV Class Error
1: GMC 1 1 0
2: M129 1 1 0
3: M. amphoriforme 1 0.95 0.025
1: GMC 1 1 0
2: M129 1 1 0
3: M. fermentans 1 1 0
1: GMC 1 1 0
2: M129 1 1 0
3: M. genitalium 1 1 0
1: GMC 0.9 1 0.05
2: M129 1 1 0
3: M. hominis 1 1 0
1: GMC 1 1 0
2: M129 1 1 0
3: M. orale 1 1 0
1: GMC 1 1 0
2: M129 1 0.95 0.025
3: M. penetrans 1 1 0
1: GMC 1 1 0
2: M129 1 1 0
3: M. pirum 1 1 0
1: GMC 1 1 0
2: M129 1 1 0
3: M. salivarium 1 0.9 0.05
1: GMC 1 1 0
2: M129 1 1 0
3: M. spermatophilum 1 0.95 0.025
For species discrimination, three categories were incorporated to cross-validate the model: either category 1: growth medium control (GMC); category 2:
M. pneumoniae (M129); or category 3: other mycoplasma species in question. Eight spectra from each category were of known class and two spectra
from each category were treated as unknowns to generate a cross-validated prediction model. Cross-validated sensitivity, specificity, and class error were
based on the classification prediction score for each category.
doi:10.1371/journal.pone.0131831.t005
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modeling, and as such, attempts to classify all 13 species within a single PLS-DA model failed
to yield statistically significant accuracy. In order to overcome this limitation and address the
question in a clinically relevant classification system, individual pair-wise PLS-DA modeling
was employed. For this analysis, we chose to focus on the nine other human commensal and
pathogenic mycoplasma species most closely related phylogentically toM. pneumoniae. Indi-
vidual PLS-DA models were built for each of the nine mycoplasma species to distinguish
among three categories: the growth medium control (1),M. pneumoniae (2), or the myco-
plasma species in question. Each model contained a total of n = 30 spectra, with 10 spectra rep-
resenting each category. Furthermore, for each category eight of the 10 spectra were of known
sample class, whereas two out of the 10 spectra were treated as unknowns and classified based
on their resemblance to category 1, 2, or 3 spectra. Cross-validation of the prediction capability
for each model was done using a Venetian blinds algorithm with five data splits. Models were
designed this way to simulate the prediction of a potential unknown clinical sample as myco-
plasma-negative,M. pneumoniae-positive, or positive for one of the other human commensal
or pathogenic mycoplasma species. The cross-validated sensitivities and specificities for all
nine models are given in Table 5. Overall, the cross-validated sensitivity and specificity was
90% or greater for all nine models, which is very promising for further application of NA-SERS
for species-level discrimination and prediction.
Conclusions
M. pneumoniae is a significant human respiratory tract pathogen in both incidence and public
health impact, but diagnostic strategies are complicated by the atypical and complex presenta-
tion of disease, non-descript symptoms, the requirement for separate tests for detection and
genotyping, and the challenges posed by direct culture. Serologic testing was historically the
gold standard for diagnosis but suffers from severe limitations that make it both unreliable and
impractical for rapid detection. Advances in qPCR technologies have overcome many issues
with sensitivity and reliability, but the cost of reagents and requirement for technical expertise
are still high, and independent tests must be done for detection and genotyping, limiting diag-
nosis by qPCR to hospital or advanced laboratory facilities and making it impractical for point-
of-care use.
We previously established that this NA-SERS biosensing platform is capable of statistically
significant detection ofM. pneumoniae in true and simulated throat swabs and has a qualitative
endpoint of detection forM. pneumoniae of< 1 cell/μl, a sensitivity exceeding that of qPCR
[13, 31]. Here, NA-SERS showed statistically significant specificity forM. pneumoniae detec-
tion regardless of clinical isolate origin, year of isolation, macrolide susceptibility phenotype, or
strain type, and was also able to distinguish allM. pneumoniae clinical isolates and control
strains from 12 other human commensal and pathogenicMollicutes species. Furthermore,
NA-SERS discriminated between the two major strain types ofM. pneumoniae with a high
degree of statistically significant accuracy and correctly identified variant strains as different
from the two major genotypes. Most importantly, NA-SERS was capable of detecting and
strain-typingM. pneumoniae within a single test and thus has the potential to facilitate tracking
epidemiological trends, such as type-switching and outbreak periodicity [12]. Studies with clin-
ical samples are ongoing, and the effect of the presence of a clinically relevant sample back-
ground, for example from a patient’s throat swab, on the ability of this platform to identify
strain types or distinguishM. pneumoniae from other human commensal and pathogenicMol-
licutes species remains to be determined. Furthermore, assessment of alternative methods of
chemometric analysis to account for the increased number of classes and modeling complexity
for species-level discrimination by NA-SERS is necessary. In addition, future clinical
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application of this technology will require collection of a larger spectral library of isolates and
background controls. However, from a point-of-care clinical standpoint, the ability to detect
M. pneumoniae rapidly is critical to informing appropriate treatment regimens consistent with
the responsible use of antimicrobials. This feature is underscored by the availability of hand-
held Raman instruments having the potential for point-of-care use [52–54]. In combination
with the minimal sample preparation requirements and expedient detection, NA-SERS shows
great promise as a platform for future application to point-of-careM. pneumoniae diagnostics.
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